Editor's note: Seeking Alpha is proud to welcome Greentrack Insights as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.The author is a european supply chain professional with extensive experience in logistics, digitalization, and political-commercial strategy within the food and agricultural sectors. The author has worked across Europe and Latin America ...

RT Santiment (@santimentfeed)🧑‍💻 Here are crypto's top Solana ecosystem projects by development. Directional indicators represent each project's ranking rise or fall since last month:➡️ 1) @solana $SOL 🥇➡️ 2) @wormholefdn $W 🥈📈 3) @driftprotocol $DRIFT 🥉📉 4) @pythnetwork $PYTH📈 5) @helium $IOT📉 6) @neonlabsorg $NEON📈 7) @swarms_corp $SWARMS📉 8) @jito_sol $JTO➡️ 9) @metaplex $MPLX📈 10) @jupiterexchange $JUP📖 Read about @santimentfeed's methodology for covering development activity for each project, objective ...

[Müzik] Merhabalar. Şimdi bugün e sunumuma bir soruyla başlamak istiyorum. Sizce başarılı bir lider günde kaç volta atıyor.Mantıklı bir cevap verebilen var mı. Herhangi bir liderim başarılı bir lider olmak adına ol neredeyse dünyanın çevresiyle ayrı mesela. >> Şimdi öncelikle eee 5 yaşındaki küçük Enes'le başlayalım hikayeye.5 yaşındaki Enes geceleri bazen uykusuz kalıyordu ve hep istediği bir şey vardı. elinde bir megafon, bir mikrofon olsun ve işte tüm dünyaya bir şeyler anlatabilsin. Eee, gecelerce bunu ...

$5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants RAMAT GAN, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced the pricing of a public offering with a single institu ...

Over $5 Million in Funding Granted to CDFIs NationwideCLEVELAND, July 28, 2025 /PRNewswire/ -- KeyBank Foundation is proud to announce the recipients of its $5.4MM special grant program designed to strengthen Community Development Financial Institutions (CDFIs). In celebration of KeyBank's (NYSE: KEY) bicentennial, the KeyBank Foundation launched a national grant initiative to support CDFIs across its 27 markets, with a focus on affordable housing and small business growth. In markets where no eligible CDFI ...

WINNEMUCCA, Nev., July 28, 2025 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) announced today that it has received approval for a two-year extension of its Conditional Use Permit (CUP) and Sage Grouse Permit (SGP) during a public meeting of the Malheur County Planning Department held on July 23rd, 2025. Paramount’s CEO Rachel Goldman stated, “We appreciate the ongoing support from Malheur County as one of our key stakeholders in the development of Grassy ...

ANCHORAGE, Alaska, July 28, 2025 /PRNewswire/ - U.S. GoldMining Inc. (NASDAQ: USGO) ("U.S. GoldMining" or the "Company") strongly commends the State of Alaska's recent announcement that the Alaska Industrial Development and Export Authority ("AIDEA") has submitted a permit application for the West Susitna Access Project ("WSAP"). This transformative infrastructure initiative will directly connect the Whistler Gold-Copper Project ("Whistler", or the "Project") via road with existing transportation infrastruc ...

Core Insights - Doubleview Gold Corp has initiated an advanced exploration program at its 90%-owned Red Spring Project, focusing on copper, silver, zinc, and gold, which reinforces its commitment to critical mineral development [1][2][4] Group 1: Red Spring Project Overview - The Red Spring Project is located in central British Columbia and has shown strong mineralization in historical drilling, particularly in its central zone [2] - The project has a 90% ownership by Doubleview and has undergone extensive previous exploration activities, including approximately 4,000 feet of drilling [2][4] Group 2: Exploration Program Details - The first phase of the 2025 exploration program includes a 3D Induced Polarization (IP) survey targeting the Angus Zone, expected to be completed by the end of August 2025 [3][4] - The 3D IP survey aims to provide insights into subsurface geology, aiding in future drill program planning [4] Group 3: Strategic Importance and Community Engagement - The Red Spring Project is strategically important for Doubleview, enhancing its focus on critical minerals and demonstrating strong potential [4] - The company is committed to sustainable exploration methods and collaborative engagement with local stakeholders and First Nations [4] Group 4: Hat Project Update - Doubleview's flagship Hat Project continues to see exploration and definition efforts, with drilling surpassing 6,500 meters in 2025 [5] - The ongoing preliminary economic assessment, metallurgy, and environmental baseline studies highlight the comprehensive advancement of the Hat polymetallic deposit [5] Group 5: Company Outlook - Doubleview anticipates that 2025 will be its most productive year to date, reflecting robust exploration and development activities across its projects [6][7]

Core Insights - Hengrui Pharma has entered into agreements with GSK to develop up to 12 innovative medicines, enhancing Hengrui's globalization strategy and providing new growth opportunities for GSK beyond 2031 [1][5] - GSK will pay $500 million in upfront fees for the agreements, which include a license for a potential best-in-class PDE3/4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease (COPD) [1][6] Group 1: Agreements and Financials - The agreements grant GSK an exclusive worldwide license for HRS-9821, aimed at treating COPD as an add-on maintenance treatment [2][8] - The total potential value of future success-based payments to Hengrui Pharma could reach approximately $12 billion if all programmes are optioned and milestones achieved [6] Group 2: Development and Collaboration - Hengrui Pharma will lead the development of the additional 11 programmes up to the completion of phase I trials, with GSK having the option to further develop and commercialize them [4][8] - The collaboration is expected to leverage GSK's R&D expertise and global clinical network, accelerating the development of innovative therapies [5][6]

Accessible version Anti-involution #2: Supply rationalization in cement, steel, metals and coal Basic Materials - Asia-Pacific Industry Overview Supply cut+ demand boost, yet near-term impact limited Following our discussion on anti-involution during our China Materials Tour (see our takeaways report on July 11 and in our Anti-involution #1 report on July 16, we note increasing news flow on supply rationalization. Initial anti-involution efforts were focused on solar, autos, building materials (including ce ...